Durvalumab is administered as an intravenous infusion, typically every two weeks. The exact dosing schedule and duration of treatment are determined by the healthcare provider based on the patient's response to therapy and any side effects experienced. Regular follow-up appointments are necessary to monitor the patient's progress and adjust treatment as needed.
